NEW YORK (GenomeWeb News) – GNS Healthcare will work with researchers at Dana-Farber Cancer Institute and Mount Sinai School of Medicine to create computer models of multiple myeloma for use in developing new therapies, the data analytics firm said today.

GNS said it will use its REFS (reverse engineering and forward simulation) platform to create network models from next-generation genome sequencing, proteomic, and clinical data.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.